Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05087888 · ClinicalTrials.gov registry record
MRI and Blood Biomarkers for the Prediction of Neurocognitive Decline Following Brain Radiation
A clinical trial of Brain Neoplasm, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- 9
- Enrollment target
- 1
- Study location
NCT05087888: Active study of Brain Neoplasm, sponsored by M.D. Anderson Cancer Center.
NCT05087888 is a study of Brain Neoplasm that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 9 participants, below the 53-participant average among 9 other Brain Neoplasm trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05087888, a study of Brain Neoplasm, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
This study determines whether non-invasive evaluation using repeated magnetic resonance imaging (MRI) scans and repeated blood biomarker measurements can be used to predict changes in a person's mental functions that result from radiation exposure to the brain. This study may let researchers monitor patient responses to treatment and the disease better and possibly make changes to patient treatment, if needed.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Magnetic Resonance Imaging
- OTHER Questionnaire Administration
- PROCEDURE Multiparametric Magnetic Resonance Imaging
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2019-08-22 |
| Est. Completion | 2027-12-31 |
What the registry record for NCT05087888 still lists
NCT05087888 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 53-participant average among 9 other Brain Neoplasm trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Brain Neoplasm appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.
NCT05087888 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05087888 about?
NCT05087888 is a clinical study titled "MRI and Blood Biomarkers for the Prediction of Neurocognitive Decline Following Brain Radiation". This study determines whether non-invasive evaluation using repeated magnetic resonance imaging (MRI) scans and repeated blood biomarker measurements can be used to predict changes in a person's mental functions that result from radiation exposure to the brain. This study may let researchers monitor...
What is the current status of trial NCT05087888?
This trial is currently active not recruiting. The enrollment target is 9 participants. The study started on 2019-08-22. Estimated completion is 2027-12-31.
What conditions does trial NCT05087888 study?
This clinical trial studies the following conditions: Brain Neoplasm.
What interventions are being tested in trial NCT05087888?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Questionnaire Administration (OTHER), Multiparametric Magnetic Resonance Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT05087888?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05087888 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05087888's enrollment target sits among peer trials
9 10th of 9 the lowest of 9 other Brain Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
Tumor Related Epilepsy
RECRUITING
-
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
RECRUITING · Phase 2
-
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
RECRUITING · NA
-
Navigated Repetitive Transcranial Magnetic Stimulation in Improving Motor Rehabilitation in Participants With Brain Tumors
ACTIVE NOT RECRUITING · NA
-
Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI